SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 103 900 KRW -0.76%
Market Cap: 8.1T KRW
Have any thoughts about
SK Biopharmaceuticals Co Ltd?
Write Note

Relative Value

The Relative Value of one SK Biopharmaceuticals Co Ltd stock under the Base Case scenario is 32 528.06 KRW. Compared to the current market price of 103 900 KRW, SK Biopharmaceuticals Co Ltd is Overvalued by 69%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
32 528.06 KRW
Overvaluation 69%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
85
vs Industry
10
Median 3Y
19.4
Median 5Y
21.8
Industry
2.5
Forward
15.5
vs History
9
vs Industry
Median 3Y
-70.9
Median 5Y
-70.9
Industry
21.8
Forward
112.6
vs History
3
vs Industry
Median 3Y
-57.3
Median 5Y
-55.7
Industry
16.1
vs History
vs Industry
Median 3Y
-85.9
Median 5Y
-79.4
Industry
23.8
vs History
37
vs Industry
2
Median 3Y
18.8
Median 5Y
20.7
Industry
2.1
vs History
85
vs Industry
10
Median 3Y
19
Median 5Y
21.2
Industry
2.7
Forward
15.2
vs History
83
vs Industry
10
Median 3Y
21.1
Median 5Y
23.6
Industry
5.2
vs History
22
vs Industry
0
Median 3Y
-42.9
Median 5Y
-50.1
Industry
13.5
Forward
79.2
vs History
16
vs Industry
Median 3Y
-41.9
Median 5Y
-53.7
Industry
16.8
Forward
95.2
vs History
3
vs Industry
Median 3Y
-55.5
Median 5Y
-54.9
Industry
15.2
vs History
3
vs Industry
Median 3Y
-52.9
Median 5Y
-51.5
Industry
19.3
vs History
72
vs Industry
8
Median 3Y
15.8
Median 5Y
17.2
Industry
1.9

Multiples Across Competitors

Competitors Multiples
SK Biopharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
8.2T KRW 15.9 141.8 94.5 119
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.4 168.9 253.1
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average P/S: 382 943.4
15.9
135%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average P/E: 44.5
141.8
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average EV/EBITDA: 423
94.5
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
168.9
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average EV/EBIT: 1 822
119
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.1
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Discover More
Back to Top